Posso obtê-lo?
Sim, se um médico decidir que é adequado para si. Semaglutide está autorizado na UE e pode ser prescrito após uma avaliação médica.
SemaglutideApenas com receita
Consulta médica online para Semaglutide.
Um médico licenciado na UE analisa o seu caso e, se for elegível, emite uma receita eletrónica válida em qualquer farmácia da UE ao abrigo da Diretiva 2011/24/UE.
- Taken just once a week
- Curbs appetite and cravings
- Studied in large clinical trials for weight loss
Iniciar consultaIniciar consulta · 25 €/mês
Reembolso total se uma avaliação não for aprovada · A medicação, se for prescrita, é dispensada e paga separadamente numa farmácia.
EM TERMOS SIMPLES
O que é Semaglutide e como obter tratamento
A semaglutida é um medicamento administrado através de uma injeção sob a pele uma vez por semana. Imita uma hormona intestinal natural chamada GLP-1 que o seu corpo produz depois de comer. Assim, sente-se saciado mais cedo e durante mais tempo e a maioria das pessoas acaba por comer menos. Na UE, o produto autorizado para o controlo do peso é Wegovy, utilizado em conjunto com uma alimentação com menos calorias e mais atividade física. A mesma substância ativa também é vendida como Ozempic, mas é um produto separado, autorizado para a diabetes tipo 2 e não para o controlo do peso.
Semaglutide está autorizado para utilização na UE desde 6 de janeiro de 2022. Por isso, um médico habilitado pode prescrevê-lo quando for clinicamente adequado para si.
Saiba mais sobre péptidos em Peptidepedia.
O que posso tomar em alternativa?
Os nossos médicos avaliam todas as opções de Perda de peso e recomendam a que melhor se adapta ao seu historial clínico e aos seus objetivos.
Veja todas as opções de Perda de pesoO que mostram os estudos?
Todos os ensaios sobre Semaglutide estão indicados abaixo, com o respetivo número de registo, o número de participantes e a indicação de que os resultados foram revistos por pares ou de que são apenas um anúncio da empresa.
Ir para os estudosEVIDÊNCIA VERIFICADA
Semaglutide: guia de evidência e regulamentação.
O QUE É
Como atua
It copies GLP-1, a hormone the gut releases after a meal, which reduces appetite and slows how quickly the stomach empties.
- GLP-1
FASE DE DESENVOLVIMENTO
Medicamento autorizado na UE
Registo de ensaios1 ensaios registados
Cada identificador NCT liga ao registo ClinicalTrials.gov. Um resultado comunicado não equivale a uma publicação revista por pares.
| ENSAIO / NCT | POPULAÇÃO | PARTICIPANTES | ESTADO | RESULTADO / CONCLUSÃO |
|---|---|---|---|---|
| STEP 1NCT03548935 | Adults with a BMI of 30 kg/m² or more, or 27 kg/m² or more with at least one weight-related condition, without type 2 diabetes; all received lifestyle counselling | 1,961 | Com resultados | 2021-03-18 |
O que os estudos comunicaram
Os resultados estão separados por fonte e grau de evidência para não confundir dados científicos com anúncios do fabricante.
Revisto por pares
Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183 (PMID 33567185)| DOSE OU GRUPO | ALTERAÇÃO MÉDIA DO PESO | SEMANAS |
|---|---|---|
| 2.4 mg once weekly | −14.9% | 68 |
| Placebo | −2.4% | 68 |
Everyone in the trial also followed a reduced-calorie diet and increased physical activity, people with type 2 diabetes were excluded, and the study measured weight only up to week 68.
SINAIS DE SEGURANÇA IDENTIFICADOS
O que foi comunicado com Semaglutide.
Nausea
Reported by 38.3% of people on semaglutide 2.4 mg versus 14.0% on placebo across the pooled STEP 1–4 phase 3 programme assessed by the EMA.
Diarrhoea
Reported by 26.8% on semaglutide 2.4 mg versus 14.3% on placebo in the same pooled programme.
Vomiting
Reported by 21.8% on semaglutide 2.4 mg versus 5.7% on placebo in the same pooled programme.
Constipation
Reported by 21.8% on semaglutide 2.4 mg versus 10.2% on placebo in the same pooled programme.
Gallbladder problems
Gallbladder-related events were reported by 2.5% on semaglutide 2.4 mg versus 1.6% on placebo, mainly gallstones (1.6% versus 1.1%).
Acute pancreatitis
Independently confirmed in 4 people (0.2%) on semaglutide 2.4 mg and 1 person (under 0.1%) on placebo in the pooled programme.
Stopping treatment because of side effects
5.7% of people on semaglutide 2.4 mg stopped treatment because of side effects versus 3.0% on placebo, mostly because of stomach and bowel symptoms.
25 €/mês (cobrado 25 € a cada 28 dias)Iniciar consulta médica
FormaCaneta pré-cheia
FrequênciaUma vez por semana
ResultadosGradual, over ~16 weeks
O que paga à Hi-Doctor25 €/mês (cobrado 25 € a cada 28 dias)
EM 60 SEGUNDOS
Semaglutide num relance
- A GLP-1 receptor agonist, given as an injection under the skin from a pen.
- Adults with a BMI of 30 or above, or 27 to under 30 with a weight-related condition.
- One injection under the skin, once a week, on the same day each week.
- Nausea and vomiting are very common; severe stomach pain can signal pancreatitis.
- Hi-Doctor consultation fee; the medicine is paid separately at a pharmacy
Sobre o tratamento
O que é Semaglutide?
Também comercializado como Ozempic, Wegovy.
Substância ativa: Semaglutide · Dosagens: 0.25 – 2.4 mg / week
Semaglutide is a GLP-1 receptor agonist — a medication that mimics a natural hormone your gut releases after eating. It reduces appetite, slows gastric emptying and helps maintain sustained weight loss when combined with supervised nutrition and activity changes.
It's prescribed alongside changes to diet and activity, as part of a medically supervised plan — not on its own, and not as a shortcut. A licensed EU doctor decides whether it's appropriate and safe for you.
COMO ATUA
O que Semaglutide faz no seu corpo
Semaglutide may reduce appetite and slow how quickly your stomach empties, so you tend to feel full sooner and eat less. Effects build gradually and vary from person to person.
It copies a natural gut hormone
Semaglutide is a close copy of GLP-1, a hormone your gut releases after you eat. It shares about 94% of the structure of the natural hormone, so it fits the same docking points on cells, but it is built to last much longer in the body.
It acts on appetite centres
Once attached to those docking points, semaglutide signals the parts of the brain that control hunger, including the hypothalamus and brainstem. In clinical studies people reported feeling full sooner, staying full for longer, feeling less hungry, and having fewer and weaker food cravings.
Eating less drives the change
Because appetite falls, most people take in fewer calories without consciously trying, and that gap is what produces weight change over months. Semaglutide also slightly slows how fast the stomach empties early after a meal, and prompts insulin release only when blood sugar is high.
Como ajuda
Three ways it supports weight loss.
Eases appetite
Acts on hunger signals, so many people feel satisfied with less food.
Slows digestion
Food stays in your stomach longer, so you tend to feel full for longer.
Part of a plan
Prescribed alongside support for diet and activity — never as a standalone fix.
O que esperar
A gradual, supervised start.
The dose is increased slowly over 16 weeks to help your body adjust and to ease side effects. Your doctor sets your exact schedule.
- Weeks 1–4 · Lowest dose
- Weeks 5–16 · Step up gradually
- Month 4+ · Maintenance dose
- Ongoing · Regular check-ins
Typical escalation
- Weeks 1–40.25 mg / week
- Weeks 5–80.5 mg / week
- Weeks 9–121 mg / week
- Weeks 13–161.7 mg / week
- Maintenanceup to 2.4 mg / week
O seu esquema é pessoal
Estes passos são apenas indicativos. O seu médico ajusta o plano à sua resposta e tolerância — e pode enviar-lhe uma mensagem em qualquer momento.
NO DIA A DIA
Usar Semaglutide no dia a dia
One injection, same day weekly
Semaglutide for weight management is injected under the skin once a week, at any time of day, with or without food. Most people pick a fixed day and set a reminder, because the weekly rhythm is easy to lose track of.
Choose and rotate injection sites
The approved sites are the abdomen, the thigh and the upper arm. The site can be changed from week to week. Rotating between sites is standard practice for injections under the skin and helps avoid repeated irritation in one spot.
Use a fresh needle every time
Attach a new needle for each injection and remove it afterwards, storing the pen without a needle attached. The product information says this helps prevent blocked needles, contamination, infection, leaking solution and inaccurate dosing. Compatible needles are 30G, 31G or 32G.
Check the liquid before injecting
Look at the solution first. It should be clear and colourless. The product information says not to use the pen if the liquid looks otherwise, or if it has been frozen at any point. Pens must never be shared between people.
Follow the pack instructions exactly
Each pen type has its own instructions for use inside the carton, and the product information asks patients to read them carefully before the first injection. With a single-dose pen you press it firmly against the skin until the yellow bar stops moving.
If you miss a dose
Take a missed dose as soon as possible, as long as fewer than five days have passed. If more than five days have gone by, skip it and take the next dose on the normal day. Ask the prescriber before restarting after several missed doses.
Moving your weekly dosing day
The day of the week can be changed if needed, provided at least three days, meaning more than 72 hours, separate one dose from the next. After moving to a new day, carry on with the once-weekly pattern from there.
Storing the pen correctly
Before first use, keep the pen in the fridge between 2°C and 8°C, away from the cooling element, and never freeze it. Keep the cap on to protect it from light. After first use a FlexTouch pen keeps for six weeks below 30°C.
Segurança primeiro
A segurança, por inteiro.
Semaglutide é um medicamento eficaz — e, como qualquer medicamento, acarreta riscos. O seu médico verifica tudo isto antes de prescrever. Este é o retrato honesto, não apenas palavras tranquilizadoras.
Efeitos secundários, por frequência
Stop and get urgent medical help if
seek medical help immediately
these need urgent attention, whatever the frequency
- Severe, persistent stomach pain, often spreading through to the back
- Sudden loss of vision, including partial loss in one eye
- Swelling of the face, lips, tongue or throat, or trouble breathing
- Severe stomach pain with bloating, vomiting and no bowel movements
- Pain under the right ribs with fever or yellowing skin
- Vomiting or diarrhoea so severe that you cannot keep fluids down
- Shakiness, confusion or sweating if you also take insulin or a sulfonylurea
Very common
very common (≥1/10)
more than 1 in 10 people
- Feeling sick (nausea)
- Being sick (vomiting)
- Diarrhoea
- Constipation
- Stomach pain
- Headache
- Tiredness
Common
common (≥1/100 to <1/10)
between 1 in 100 and 1 in 10 people
- Dizziness
- Altered sense of taste
- Unusual skin sensations such as tingling or numbness
- Indigestion, heartburn or acid reflux
- Inflammation of the stomach lining (gastritis)
- Burping, wind or a bloated stomach
- Gallstones
- Hair loss
- Reactions where the injection was given
- Low blood sugar, in people who also have type 2 diabetes
- Worsening of diabetic eye disease, in people with type 2 diabetes
Uncommon
uncommon (≥1/1,000 to <1/100)
between 1 in 1,000 and 1 in 100 people
- Inflammation of the pancreas (acute pancreatitis)
- The stomach emptying more slowly than usual
- A faster heart rate
- Low blood pressure
- Feeling dizzy on standing up (orthostatic hypotension)
- Raised amylase and lipase, two pancreatic enzymes, in blood tests
Rare
rare (≥1/10,000 to <1/1,000)
between 1 in 10,000 and 1 in 1,000 people
- Severe allergic reaction affecting the whole body (anaphylaxis)
- Swelling of the face, lips, tongue or throat (angioedema)
Very rare
very rare (<1/10,000)
fewer than 1 in 10,000 people
- Sudden loss of vision caused by damage to the optic nerve
Reported, frequency not known
frequency not known
reported after the medicine was licensed; how often is not established
- Blockage of the bowel (intestinal obstruction)
Adultos com obesidade (IMC ≥30) ou com excesso de peso (IMC ≥27) mais pelo menos uma condição relacionada com o peso, como diabetes tipo 2, hipertensão ou dislipidemia.
- Autoinjeção uma vez por semana na coxa, abdómen ou parte superior do braço.
- A dose é aumentada gradualmente (0,25 mg → 0,5 → 1,0 → 1,7 → 2,4 mg) ao longo de 16 semanas para limitar os efeitos secundários gastrointestinais.
- Combinado com dieta e atividade física — o semaglutido não é um substituto para a mudança de estilo de vida.
QUEM NÃO DEVE TOMAR E QUEM PRECISA DE PRECAUÇÃO
- You have ever had an allergic reaction to semaglutide or any ingredient in the pen
- You are pregnant, planning a pregnancy within the next two months, or breastfeeding
- You have type 1 diabetes, because semaglutide is not a substitute for insulin
- You already take another GLP-1 receptor agonist, as the combination has not been evaluated
- You take another prescription weight-management medicine at the same time
- You have severe kidney impairment, including end-stage kidney disease
- You have severe liver impairment
- You have severe gastroparesis, a condition where the stomach empties very slowly
- You have congestive heart failure classed as New York Heart Association class IV
- You have type 2 diabetes with uncontrolled or unstable diabetic eye disease
Quando procurar cuidados urgentes
Perante sintomas graves, súbitos ou inesperados, ligue para o número de emergência local ou dirija-se às urgências mais próximas. Depois, informe o seu médico através do chat da sua conta.
Medicamentos e substâncias que interagem
| MEDICAMENTO OU SUBSTÂNCIA | O QUE PODE ACONTECER | O QUE FAZ O MÉDICO |
|---|---|---|
| Warfarin and other coumarin blood thinners | Cases of a reduced INR clotting measure have been reported alongside semaglutide. | Prescriber arranges more frequent INR blood tests when semaglutide is started. |
| Insulin | Combined with semaglutide in type 2 diabetes, the risk of low blood sugar rises. | Prescriber may lower the insulin dose at the start and monitor blood sugar. |
| Sulfonylureas (e.g. gliclazide) | Also raise the risk of low blood sugar when taken alongside semaglutide. | Prescriber may reduce the sulfonylurea dose when semaglutide is introduced. |
| Oral medicines needing fast absorption | Semaglutide slows stomach emptying, which could in principle affect how they are absorbed. | Prescriber uses caution and reviews whether timing or monitoring needs changing. |
| Combined oral contraceptives | No clinically relevant change; levonorgestrel exposure rose 20%, ethinylestradiol was unaffected. | No dose change needed. Contraception is advised while taking semaglutide. |
| Paracetamol | Peak levels fell 23% with semaglutide 1 mg, but total exposure was unchanged. | No dose adjustment of paracetamol is required. |
| Atorvastatin | Peak level fell 38% but overall exposure was unchanged, judged not clinically relevant. | No dose adjustment is required. |
| Digoxin and metformin | Semaglutide did not change overall exposure or peak levels of either medicine. | No dose adjustment is required. |
Peça a um médico para analisar o seu casoÉ exatamente isto que o médico verifica antes de prescrever seja o que for.
Leia o resumo de segurança completo de SemaglutideEVIDÊNCIA
O que os ensaios clínicos encontraram
The weight-management evidence for semaglutide comes from the STEP trial programme, and its cardiovascular evidence comes from the SELECT trial.
1,961 adults with overweight or obesity, without diabetes · 68 weeks
STEP 1. The placebo group changed -2.4%.
Fonte: STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity1,961 adults with overweight or obesity, without diabetes · 68 weeks
STEP 1. The placebo group lost 2.6 kg. Estimated treatment difference -12.7 kg (95% CI -13.7 to -11.7).
Fonte: STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity1,961 adults with overweight or obesity, without diabetes · 68 weeks
STEP 1, versus 12.0% on placebo. Half the semaglutide group (50.5%) lost 15% or more.
Fonte: STEP 1: Once-Weekly Semaglutide in Adults with Overweight or ObesityAdults who completed a 20-week run-in up to the 2.4 mg dose · 48 weeks, from week 20 to week 68
STEP 4. Those switched to placebo regained weight. Difference -14.8 percentage points.
Fonte: STEP 4: Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance17,604 adults aged 45+ with existing cardiovascular disease and BMI 27+, no diabetes
SELECT. Events occurred in 6.5% on semaglutide versus 8.0% on placebo.
Fonte: SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesThese figures are averages across large groups, not a forecast for any one person. In STEP 1 the middle of the group lost close to 15% of their starting weight over 68 weeks, but individual results ranged from substantial loss to almost none, and everyone in the trial was also following a reduced-calorie diet and increased physical activity. STEP 4 is the important counterpoint: weight came back when treatment stopped, so this is a long-term treatment rather than a short course, and whether it is right for you is a decision for the prescribing doctor.
ALTERNATIVAS
Weight-management medicines authorised in the EU
| MEDICAMENTO | COMO SE ADMINISTRA | COM QUE FREQUÊNCIA | INTERVALO DE DOSE HABITUAL | INDICAÇÃO AUTORIZADA NA UE | EVIDÊNCIA PRINCIPAL |
|---|---|---|---|---|---|
| Semaglutide | Injeção semanal | Uma vez por semana | 0.25-2.4 mg | Weight management alongside a reduced-calorie diet and more physical activity, in adults with a BMI of 30 or above, or 27 to under 30 with a weight-related condition. | STEP 1: mean -14.9% body weight at 68 weeks |
| Tirzepatide | Injeção semanal | Uma vez por semana | 2.5-15 mg | Weight management alongside a reduced-calorie diet and more physical activity, in adults with a BMI of 30 or above, or 27 or above with a weight-related condition. Also authorised for type 2 diabetes. | EMA: about 15% mean weight reduction over 72 weeks |
| Liraglutide | Injeção diária | Uma vez por dia | 0.6-3.0 mg | Weight management alongside a reduced-calorie diet and more physical activity, in adults with a BMI of 30 or above, or 27 to under 30 with a weight-related condition. | EMA: 7.5% mean weight reduction versus 2.3% on placebo |
| Orlistat | Cápsula oral | Até três vezes por dia com as refeições | 120 mg per meal | Treatment of obesity alongside a mildly reduced-calorie diet, in patients with a BMI of 30 or above, or above 28 with associated risk factors. | EMA: mean 6.1 kg lost over one year versus 2.6 kg |
Não sabe qual se adequa ao seu caso? O médico analisa o seu historial e diz-lhe.
Iniciar consulta · 25 €/mêsACESSO E CUSTO
Como obter Semaglutide e quanto custa
Semaglutide is a prescription-only medicine everywhere in the EU, so it cannot be bought over the counter in any of these countries. Whether the national health system pays for it when it is prescribed for weight management is decided country by country, and in most of these markets it is not covered, meaning the patient pays.
O que paga à Hi-Doctor
25 €/mês (cobrado 25 € a cada 28 dias)
Responda a algumas perguntas e um médico licenciado na UE analisa o seu caso em menos de 2 horas, em média. Reembolso total se não for adequado para si.
O que a farmácia cobra
A Hi-Doctor não vende, não armazena nem dispensa medicamentos e não define o seu preço. O medicamento é pago à parte na farmácia e o valor depende do país, da embalagem, da existência de genérico e da comparticipação. A base de dados oficial ligada na tabela publica o preço autorizado em vigor.
| PAÍS | REGIME DE DISPENSA | COMPARTICIPADO PELO SISTEMA DE SAÚDE? | FONTE OFICIAL |
|---|---|---|---|
| Espanha | Medicamento sujeito a receita médica | Not reimbursed for weight management | AEMPS CIMA |
Ver os outros países
| Alemanha | Medicamento sujeito a receita médica | Excluded by law from statutory cover | PharmNet.Bund AMIce |
|---|---|---|---|
| França | Medicamento sujeito a receita médica | Restricted — see national criteria | Base de données publique des médicaments |
| Itália | Medicamento sujeito a receita médica | Not reimbursed for weight management | AIFA Medicinali |
| Países Baixos | Medicamento sujeito a receita médica | Not reimbursed for weight management | CBG-MEB Geneesmiddeleninformatiebank |
| Portugal | Medicamento sujeito a receita médica | Not reimbursed for weight management | INFARMED Infomed |
| Bélgica | Medicamento sujeito a receita médica | Not reimbursed for weight management | FAGG-AFMPS medicines database |
| Irlanda | Medicamento sujeito a receita médica | Not reimbursed for weight management | HPRA Find a Medicine |
| Áustria | Medicamento sujeito a receita médica | Restricted — see national criteria | BASG Medikamente Info Austria |
| Polónia | Medicamento sujeito a receita médica | Not reimbursed for weight management | Rejestr Produktów Leczniczych |
PREÇOS
Só paga se o tratamento for aprovado.
25 €/mês para perda de peso ou 15 €/mês (cobrado 45 € a cada 90 dias) para crescimento capilar. Para saúde sexual está disponível uma consulta pontual de 35 €.
Perda de peso
PLANO CONTÍNUO
25 €/mês
Cobrado 25 € a cada 28 dias · cancele a qualquer momento
Ciclo de tratamento de 28 dias
Para tratamento contínuo e renovações revistas pelo seu médico.
Renovações revistas pelo seu médico
Iniciar consulta
Reembolso total se uma avaliação não for aprovada
O QUE ESTÁ INCLUÍDO
- Primeira consulta incluída
- Renovações revistas pelo seu médico
- Cuidados contínuos com o seu médico
- Cancele a qualquer momento
Reembolso total se uma avaliação não for aprovada
Se uma avaliação não for aprovada, devolvemos a taxa de 25 € desse período e cancelamos o plano.
Nota: A medicação, se o médico a prescrever, é paga separadamente na farmácia ao preço que esta definir. A Hi-Doctor não vende medicamentos.
COMO DECIDE O MÉDICO
Um médico inscrito na Ordem analisa o seu caso, não um algoritmo
Um médico habilitado na UE lê o seu questionário e responde em menos de 2 horas, em média.
Se o médico decidir que não é seguro prescrever, o valor da consulta é reembolsado na íntegra.
O acompanhamento decorre no chat privado da sua conta, em conformidade com o RGPD. Sem WhatsApp, sem SMS.
PERGUNTAS FREQUENTES
Perguntas sobre Semaglutide.
OUTROS TRATAMENTOS DE PERDA DE PESO
Explore tratamentos relacionados.
FONTES
De onde vem esta informação
- 01
Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 02
Wegovy: Annex I Summary of Product Characteristics (EU product information) — European Medicines Agency, 2026
- 03
Wegovy (semaglutide): European Public Assessment Report overview — European Medicines Agency, 2026
- 04
Ozempic (semaglutide) solution for injection: Summary of Product Characteristics, type 2 diabetes indication — electronic medicines compendium (emc), 2026
- 05
STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity — New England Journal of Medicine (Wilding JPH et al., 384:989-1002), 2021
- 06
STEP 4: Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance — JAMA (Rubino D et al., 325:1414-1425), 2021
- 07
SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes — New England Journal of Medicine (Lincoff AM et al., 389:2221-2232), 2023
- 08
Semaglutide (Wegovy, Ozempic, Rybelsus): NHS medicines A to Z — National Health Service (UK), 2026
- 09
Wegovy FlexTouch: authorisation and supply classification record — AEMPS CIMA (Spain), 2026
- 10
Ficha técnica Wegovy 2,4 mg FlexTouch: EU Summary of Product Characteristics, section 4.8 adverse reaction table — AEMPS CIMA (Spain), 2026
- 11
Situación de financiación de medicamentos: Wegovy 2,4 mg, national code 758089 — Ministerio de Sanidad (Spain), 2023
- 12
G-BA implements the statutory prescribing exclusion for the weight-loss medicine Wegovy — Gemeinsamer Bundesausschuss (Germany), 2024
- 13
Obésité: de nouveaux médicaments peuvent être pris en charge dans des conditions encadrées — Assurance Maladie / ameli.fr (France), 2026
- 14
Wegovy niet vergoeden uit het basispakket: GVS advice on semaglutide for obesity — Zorginstituut Nederland, 2024
- 15
Medicines to treat obesity: reimbursement status of semaglutide in Ireland — Health Service Executive (Ireland), 2026
- 16
Obwieszczenie Ministra Zdrowia: wykaz refundowanych leków (pharmacy reimbursement list) — Ministerstwo Zdrowia (Poland), 2026
- 17
Rejestr Produktów Leczniczych: Wegovy (semaglutidum) registration record, ATC A10BJ06 — Rejestry Medyczne / e-Zdrowie (Poland), 2026
- 18
Behandlungspfad Übergewicht & Adipositas: case-by-case consideration of weight-reduction medicines — Dachverband der österreichischen Sozialversicherung (Austria), 2026
- 19
Warning on falsified GLP-1 receptor agonists: prescription status and pharmacy-only supply in Austria — Bundesamt für Sicherheit im Gesundheitswesen (BASG, Austria), 2026
- 20
Nieuwigheden geneesmiddelen: Wegovy commercialised in Belgium, not reimbursed for obesity — Belgisch Centrum voor Farmacotherapeutische Informatie (BCFI/CBIP), 2025
- 21
Wegovy FlexTouch: INFARMED market authorisation notice and semaglutide safety communication — INFARMED, I.P. (Portugal), 2026
- 22
Nuovi farmaci per il diabete e l'obesità: AIFA guide to responsible use, Wegovy class C classification — Agenzia Italiana del Farmaco (AIFA), 2026
- 23
Mounjaro (tirzepatide): European Public Assessment Report overview — European Medicines Agency, 2026
- 24
Saxenda (liraglutide): European Public Assessment Report overview — European Medicines Agency, 2026
- 25
Saxenda 6 mg/mL solution for injection: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 26
Xenical (orlistat): European Public Assessment Report overview — European Medicines Agency, 2026
Revisto pela equipa médica da Hi-Doctor · Última revisão 2026-07-27 · Próxima revisão prevista em 2027-07-27
Esta página contém informação sobre um medicamento; não é uma recomendação para o tomar nem substitui uma consulta médica. Só um médico habilitado que tenha analisado o seu historial pode decidir se um tratamento é adequado para si.
Descubra se é adequado para si
Veja se Semaglutide é apropriado para si.
Responda a algumas perguntas e um médico licenciado na UE analisa o seu caso em menos de 2 horas, em média. Reembolso total se não for adequado para si.